Contrave vs. Wegovy: cravings, GLP-1 effects, and precautions

Contrave combines naltrexone and bupropion; Wegovy contains semaglutide. They work through different pathways and need different safety screening. Compare the named products and their uses in MedlinePlus naltrexone and bupropion and MedlinePlus semaglutide injection. Clinical similarity between Contrave and Wegovy does not make their instructions interchangeable. Ask why Contrave or Wegovy fits the documented diagnosis.

MedlinePlus describes the naltrexone–bupropion combination as affecting appetite and cravings and notes that its bupropion component also appears in other medicines. This makes a full medication list especially important. Semaglutide’s guide focuses on a different collection of adverse effects and contraindications. Neither description proves that a person whose eating feels driven by cravings should automatically use Contrave. NIDDK places medicine within a broader weight-management plan. See NIDDK prescription weight-management medicines. Evidence for Contrave cannot automatically establish a result with Wegovy.

Review seizure history, opioid use, blood pressure, pregnancy plans, mood symptoms and other drugs with the prescriber before considering Contrave. For Wegovy, discuss product-specific warnings and digestive effects. The clinician may recommend neither after reviewing the whole history. Check the specific warnings and patient instructions in MedlinePlus naltrexone and bupropion and MedlinePlus semaglutide injection. Let the prescriber direct any change from Contrave to Wegovy; follow the dispensed package.

Ask what outcome will be measured, when treatment will be reassessed, and what to do if symptoms occur. Compare the exact insurance and pharmacy pathway, not a generic “weight-loss medication” price. For Contrave or Wegovy, confirm the pharmacy, coverage and reassessment date. For a compounded form of Contrave, request the medical rationale and directly applicable evidence.

A patient using opioid pain treatment should flag that before considering naltrexone–bupropion. A patient already taking bupropion should flag possible duplication. For semaglutide, discuss its labeled contraindications and digestive tolerability. These are concrete screening questions, not an argument that a craving-related symptom identifies the right drug. If the person has seizure history, uncontrolled blood pressure, opioid treatment or another bupropion prescription, those facts can change the Contrave discussion. With Wegovy, review the current product label for its distinct warnings. The clinician may recommend a different medicine or no medicine; the comparison is a screening framework, not a selection rule. Include every prescription and over-the-counter medicine in the review, not only other weight treatments.